Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):480–487. doi: 10.1054/bjoc.1999.0946

Anti-tumour activity of tachykinin NK1receptor antagonists on human glioma U373 MG xenograft

C Palma 1, M Bigioni 1, C Irrissuto 1, F Nardelli 1, C A Maggi 2, S Manzini 1
PMCID: PMC2363296  PMID: 10646908

Abstract

Astrocytes harbour functional receptors to many neurotransmitters, including substance P (SP), an undecapeptide belonging to the tachykinin family of peptide transmitters. SP activates malignant glial cells to induce cytokine release and proliferation, both responses being relevant for tumour progression. In tumours developed in nude mice transplanted subcutaneously (s.c.) to U373 MG human glioma cells, the presence of SP was observed at immunohistochemistry. Although the administration of exogenous SP did not significantly affect the size or development of U373 MG xenograft, a role of SP in supporting glioma progression in vivo was highlighted by the tumour growth inhibition induced by highly specific and selective human tachykinin NK1receptor antagonists (MEN 11467 and MEN 11149). The anti-tumour activity of MEN 11467 was observed both with s.c. or intravenous treatments and was partially reverted by the concomitant administration of exogenous SP. Doxorubicin did not show any activity in controlling U373 MG growth in this in vivo model. A novel therapeutic approach to treat malignant gliomas with tachykinin NK1receptor antagonists is suggested by these findings. © 2000 Cancer Research Campaign

Keywords: glioma, tumour xenograft, substance P, tachykinin NK1receptor antagonist, anti-tumour activity

Full Text

The Full Text of this article is available as a PDF (749.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J. M., Hoyle N. R., Yeats J. C., Ghatei M. A., Thomas D. G., Bloom S. R. Neuropeptides in neurological tumours. J Neurooncol. 1985;3(3):197–202. doi: 10.1007/BF00165179. [DOI] [PubMed] [Google Scholar]
  2. Cirillo R., Astolfi M., Conte B., Lopez G., Parlani M., Terracciano R., Fincham C. I., Manzini S. Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist. Eur J Pharmacol. 1998 Jan 12;341(2-3):201–209. doi: 10.1016/s0014-2999(97)01453-2. [DOI] [PubMed] [Google Scholar]
  3. Gitter B. D., Regoli D., Howbert J. J., Glasebrook A. L., Waters D. C. Interleukin-6 secretion from human astrocytoma cells induced by substance P. J Neuroimmunol. 1994 Apr;51(1):101–108. doi: 10.1016/0165-5728(94)90134-1. [DOI] [PubMed] [Google Scholar]
  4. Giuliani F. C., Zirvi K. A., Kaplan N. O. Therapeutic response of human tumor xenografts in athymic mice to doxorubicin. Cancer Res. 1981 Jan;41(1):325–335. [PubMed] [Google Scholar]
  5. Hennig I. M., Laissue J. A., Horisberger U., Reubi J. C. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer. 1995 Jun 9;61(6):786–792. doi: 10.1002/ijc.2910610608. [DOI] [PubMed] [Google Scholar]
  6. Heuillet E., Ménager J., Fardin V., Flamand O., Bock M., Garret C., Crespo A., Fallourd A. M., Doble A. Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG. J Neurochem. 1993 Mar;60(3):868–876. doi: 10.1111/j.1471-4159.1993.tb03231.x. [DOI] [PubMed] [Google Scholar]
  7. Humpel C., Marksteiner J., Saria A. Glial-cell-line-derived neurotrophic factor enhances biosynthesis of substance P in striatal neurons in vitro. Cell Tissue Res. 1996 Nov;286(2):249–255. doi: 10.1007/s004410050694. [DOI] [PubMed] [Google Scholar]
  8. Jennings M. T., Maciunas R. J., Carver R., Bascom C. C., Juneau P., Misulis K., Moses H. L. TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int J Cancer. 1991 Aug 19;49(1):129–139. doi: 10.1002/ijc.2910490124. [DOI] [PubMed] [Google Scholar]
  9. Kostyk S. K., Kowall N. W., Hauser S. L. Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res. 1989 Dec 18;504(2):284–288. doi: 10.1016/0006-8993(89)91369-3. [DOI] [PubMed] [Google Scholar]
  10. Lee C. M., Tung W. L., Young J. D. Tachykinin-stimulated inositol phospholipid hydrolysis and taurine release from human astrocytoma cells. J Neurochem. 1992 Aug;59(2):406–414. doi: 10.1111/j.1471-4159.1992.tb09386.x. [DOI] [PubMed] [Google Scholar]
  11. Luo W., Sharif T. R., Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res. 1996 Nov 1;56(21):4983–4991. [PubMed] [Google Scholar]
  12. Maggi C. A., Patacchini R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol. 1993 Feb;13(1):23–93. doi: 10.1111/j.1474-8673.1993.tb00396.x. [DOI] [PubMed] [Google Scholar]
  13. Mantyh P. W., Johnson D. J., Boehmer C. G., Catton M. D., Vinters H. V., Maggio J. E., Too H. P., Vigna S. R. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci U S A. 1989 Jul;86(13):5193–5197. doi: 10.1073/pnas.86.13.5193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Michel J. P., Sakamoto N., Bouvier R., Tommasi M., Pearson J. Substance P-immunoreactive astrocytes related to deep white matter and striatal blood vessels in human brain. Brain Res. 1986 Jul 9;377(2):383–387. doi: 10.1016/0006-8993(86)90886-3. [DOI] [PubMed] [Google Scholar]
  15. Muñoz-Fernández M. A., Fresno M. Involvement of nitric oxide on the cytokine induced growth of glial cell. Biochem Biophys Res Commun. 1993 Jul 15;194(1):319–325. doi: 10.1006/bbrc.1993.1822. [DOI] [PubMed] [Google Scholar]
  16. Ogo H., Kuroyanagi N., Inoue A., Nishio H., Hirai Y., Akiyama M., DiMaggio D. A., Krause J. E., Nakata Y. Human astrocytoma cells (U-87 MG) exhibit a specific substance P binding site with the characteristics of an NK-1 receptor. J Neurochem. 1996 Nov;67(5):1813–1820. doi: 10.1046/j.1471-4159.1996.67051813.x. [DOI] [PubMed] [Google Scholar]
  17. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 1993 Apr;73(2):229–308. doi: 10.1152/physrev.1993.73.2.229. [DOI] [PubMed] [Google Scholar]
  18. Palma C., Manzini S. Substance P induces secretion of immunomodulatory cytokines by human astrocytoma cells. J Neuroimmunol. 1998 Jan;81(1-2):127–137. doi: 10.1016/s0165-5728(97)00167-7. [DOI] [PubMed] [Google Scholar]
  19. Palma C., Minghetti L., Astolfi M., Ambrosini E., Silberstein F. C., Manzini S., Levi G., Aloisi F. Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. Glia. 1997 Oct;21(2):183–193. doi: 10.1002/(sici)1098-1136(199710)21:2<183::aid-glia2>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  20. Palma C., Nardelli F., Manzini S. Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists. Eur J Pharmacol. 1999 Jun 25;374(3):435–443. doi: 10.1016/s0014-2999(99)00334-9. [DOI] [PubMed] [Google Scholar]
  21. Palma C., Nardelli F., Manzini S., Maggi C. A. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer. 1999 Jan;79(2):236–243. doi: 10.1038/sj.bjc.6690039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Palma C., Urbani F., Manzini S. Interleukin-6 production by U373 MG, a human astrocytoma cell line: different pathways involved in substance P and lipopolysaccharide activation. J Neuroimmunol. 1995 Jun;59(1-2):155–163. doi: 10.1016/0165-5728(95)00040-9. [DOI] [PubMed] [Google Scholar]
  23. Quartara L., Maggi C. A. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides. 1998 Feb;32(1):1–49. doi: 10.1016/s0143-4179(98)90015-4. [DOI] [PubMed] [Google Scholar]
  24. Sharif M. Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines. Int J Oncol. 1998 Feb;12(2):273–286. doi: 10.3892/ijo.12.2.273. [DOI] [PubMed] [Google Scholar]
  25. Walther W., Stein U., Pfeil D. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. Int J Cancer. 1995 Jun 9;61(6):832–839. doi: 10.1002/ijc.2910610615. [DOI] [PubMed] [Google Scholar]
  26. Yamazaki K., Moriya H., Ichihara N., Mitsushio H., Inagaki S., Kikuchi T. Substance P-immunoreactive astrocytes in gracile sensory nervous tract of spinal cord in gracile axonal dystrophy mutant mouse. Mol Chem Neuropathol. 1993 Sep;20(1):1–20. doi: 10.1007/BF03160066. [DOI] [PubMed] [Google Scholar]
  27. Ziche M., Morbidelli L., Pacini M., Geppetti P., Alessandri G., Maggi C. A. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990 Sep;40(2):264–278. doi: 10.1016/0026-2862(90)90024-l. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES